Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Buprenex

×

Overview

What is Buprenex?

BUPRENEX (buprenorphine hydrochloride) is a partial opioid agonist.

The chemical name of buprenorphine hydrochloride is 17-(cyclopropylmethyl)-α-(1, 1-dimethylethyl)-4, 5-epoxy-18, 19-dihydro-3-hydroxy-6-methoxy-α-methyl-6, 14-ethenomorphinan-7-methanol, hydrochloride [5α, 7α(S)].

Buprenorphine hydrochloride is a white powder, weakly acidic and with limited solubility in water.

BUPRENEX is a clear, sterile, injectable agonist-antagonist analgesic intended for intravenous or intramuscular administration. Each ml of BUPRENEX contains 0.324 mg buprenorphine hydrochloride (equivalent to 0.3 mg buprenorphine), 50 mg dextrose (as monohydrate), water for injection and HCI to adjust pH.

Buprenorphine hydrochloride has the molecular formula, CHNOHCl, and the following structure:

       



What does Buprenex look like?



What are the available doses of Buprenex?

Sorry No records found.

What should I talk to my health care provider before I take Buprenex?

Sorry No records found

How should I use Buprenex?

BUPRENEX is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.

Use the lowest effective dosage for the shortest duration consistent with individual patients treatment goals

Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse

Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with BUPRENEX and adjust the dosage accordingly .


What interacts with Buprenex?

Sorry No Records found


What are the warnings of Buprenex?

Sorry No Records found


What are the precautions of Buprenex?

Sorry No Records found


What are the side effects of Buprenex?

Sorry No records found


What should I look out for while using Buprenex?

BUPRENEX is contraindicated in patients with:


What might happen if I take too much Buprenex?


How should I store and handle Buprenex?

BUPRENEX (buprenorphine hydrochloride) is supplied in cartons containing five clear glass snap-ampules of 0.3 mg/mL buprenorphine). NDCStore at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [USP Controlled Room Temperature]. Protect from prolonged exposure to light. Manufactured by: Reckitt Benckiser Healthcare (UK) Ltd., Indivior Inc., BUPRENEX (buprenorphine hydrochloride) is supplied in cartons containing five clear glass snap-ampules of 0.3 mg/mL buprenorphine). NDCStore at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [USP Controlled Room Temperature]. Protect from prolonged exposure to light. Manufactured by: Reckitt Benckiser Healthcare (UK) Ltd., Indivior Inc., BUPRENEX (buprenorphine hydrochloride) is supplied in cartons containing five clear glass snap-ampules of 0.3 mg/mL buprenorphine). NDCStore at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [USP Controlled Room Temperature]. Protect from prolonged exposure to light. Manufactured by: Reckitt Benckiser Healthcare (UK) Ltd., Indivior Inc., BUPRENEX (buprenorphine hydrochloride) is supplied in cartons containing five clear glass snap-ampules of 0.3 mg/mL buprenorphine). NDCStore at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [USP Controlled Room Temperature]. Protect from prolonged exposure to light. Manufactured by: Reckitt Benckiser Healthcare (UK) Ltd., Indivior Inc., BUPRENEX (buprenorphine hydrochloride) is supplied in cartons containing five clear glass snap-ampules of 0.3 mg/mL buprenorphine). NDCStore at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [USP Controlled Room Temperature]. Protect from prolonged exposure to light. Manufactured by: Reckitt Benckiser Healthcare (UK) Ltd., Indivior Inc., BUPRENEX (buprenorphine hydrochloride) is supplied in cartons containing five clear glass snap-ampules of 0.3 mg/mL buprenorphine). NDCStore at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). [USP Controlled Room Temperature]. Protect from prolonged exposure to light. Manufactured by: Reckitt Benckiser Healthcare (UK) Ltd., Indivior Inc.,


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. One unusual property of Buprenex observed in studies is its very slow rate of dissociation from its receptor. This could account for its longer duration of action than morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence.

Non-Clinical Toxicology
BUPRENEX is contraindicated in patients with:

General:

Because BUPRENEX is metabolized by the liver, the activity of BUPRENEX may be increased and/or extended in those individuals with impaired hepatic function or those receiving other agents known to decrease hepatic clearance.

BUPRENEX has been shown to increase intracholedochal pressure to a similar degree as other opioid analgesics, and thus should be administered with caution to patients with dysfunction of the biliary tract.

The most frequent side effect in clinical studies involving 1,133 patients was sedation which occurred in approximately two-thirds of the patients. Although sedated, these patients could easily be aroused to an alert state.

Other less frequent adverse reactions occurring in 5-10% of the patients were:

Nausea Dizziness/Vertigo

Occurring in 1-5% of the patients:

Sweating Headache

Hypotension Nausea/Vomiting

Vomiting Hypoventilation

Miosis

The following adverse reactions were reported to have occurred in less than 1% of the patients:

CNS Effect:

Cardiovascular:

Gastrointestinal:

Respiratory:

Dermatological:

Ophthalmological:

Miscellaneous:

Other effects observed infrequently include malaise, hallucinations, depersonalization, coma, dyspepsia, flatulence, apnea, rash, amblyopia, tremor, and pallor.

The following reactions have been reported to occur rarely: loss of appetite, dysphoria/agitation, diarrhea, urticaria, and convulsions/lack of muscle coordination.

Allergic Reactions:

In the United Kingdom, buprenorphine hydrochloride was made available under monitored release regulation during the first year of sale, and yielded data from 1,736 physicians on 9,123 patients (17,120 administrations). Data on 240 children under the age of 18 years were included in this monitored release program. No important new adverse effects attributable to buprenorphine hydrochloride were observed.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).